SUMO2/3 anticorps

N° du produit ABIN6945095

Détail du produit anti-SUMO2/3 anticorps

Antigène: SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp SUMO2/3 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: C terminal Human Sumo 2+3

Clone: 7G10

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IF(ICC) 1:50-200
IHC()

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 1xTBS ( pH 7.4), 1 % BSA, 40 %Glycerol and 0.05 % Sodium Azide.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur SUMO2/3

Antigène: SUMO2/3 (Small Ubiquitin Related Modifier 2/3 (SUMO2/3))

Autre désignation: Sumo 2+3 (SUMO2/3 Produits)

Synonymes: anticorps SUMO2, anticorps small ubiquitin-like modifier 2, anticorps SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)-like, anticorps small ubiquitin-related modifier 2, anticorps SUMO2, anticorps LOC711990, anticorps LOC714892

Sujet:

Synonyms: Small ubiquitin-related modifier 2, HSMT3, SMT3 homolog 2, SUMO-3, Sentrin-2, Ubiquitin-like protein SMT3B, Small ubiquitin-related modifier 3, SMT3 homolog 1, SUMO-2, Ubiquitin-like protein SMT3A, SUMO-2, Smt3B, SUMO2, SUMO-3, Smt3A, SUMO3

Background: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, SUMO-2 and SUMO-3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2, and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, SUMO-2 and SUMO-3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include IkBa, MDM2, p53, PML and Ran GAP1. SUMO-2 and SUMO-3 contribute to a greater percentage of protein modification than does SUMO-1, and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates b-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

UniProt: P55854, P61956